[HTML][HTML] Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer
E Juhász, JH Kim, G Klingelschmitt, S Walzer - European Journal of Cancer, 2013 - Elsevier
INTRODUCTION: Maintenance therapy can delay progression and prolong survival in
metastatic non-small-cell lung cancer (mNSCLC). As treatment for mNSCLC is non-curative …
metastatic non-small-cell lung cancer (mNSCLC). As treatment for mNSCLC is non-curative …
[引用][C] Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer
E JUHASZ, JH KIM… - European journal of …, 2013 - pascal-francis.inist.fr
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life
of patients with metastatic non-small-cell lung cancer CNRS Inist Pascal-Francis CNRS Pascal and …
of patients with metastatic non-small-cell lung cancer CNRS Inist Pascal-Francis CNRS Pascal and …
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer
E Juhász, JH Kim, G Klingelschmitt… - European Journal of …, 2013 - ejcancer.com
Introduction Maintenance therapy can delay progression and prolong survival in metastatic
non-small-cell lung cancer (mNSCLC). As treatment for mNSCLC is non-curative, its impact …
non-small-cell lung cancer (mNSCLC). As treatment for mNSCLC is non-curative, its impact …
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.
E Juhász, JH Kim, G Klingelschmitt… - European Journal of …, 2013 - europepmc.org
Results Compared with placebo, erlotinib maintenance therapy prolonged progression-free
and overall survival by 41% and 23%, respectively. At baseline, HRQoL measures were …
and overall survival by 41% and 23%, respectively. At baseline, HRQoL measures were …
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer
E Juhász, JH Kim, G Klingelschmitt… - European Journal of …, 2013 - infona.pl
Maintenance therapy can delay progression and prolong survival in metastatic non-small-
cell lung cancer (mNSCLC). As treatment for mNSCLC is non-curative, its impact on patient …
cell lung cancer (mNSCLC). As treatment for mNSCLC is non-curative, its impact on patient …
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer
E Juhász, JH Kim, G Klingelschmitt, S Walzer - 2013 - pubmed.ncbi.nlm.nih.gov
Introduction Maintenance therapy can delay progression and prolong survival in metastatic
non-small-cell lung cancer (mNSCLC). As treatment for mNSCLC is non-curative, its impact …
non-small-cell lung cancer (mNSCLC). As treatment for mNSCLC is non-curative, its impact …